Toxicokinetics and Perfluorooctanesulfonic Acid-Induced Liver Protein Expression Are Markedly Altered in Mice Lacking Albumin
Chemical Research in Toxicology · 21.07.2025 · 38 (7) · 1183-1191
DOI: 10.1021/acs.chemrestox.4c00508 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Research in Toxicology, online erschienen am 10.06.2025. Verfasst von Emily M Kaye und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, 7 Greenhouse Rd, Kingston, Rhode Island 02881,…. Hauptthemen laut MEDLINE: Fluorocarbons, Alkanesulfonic Acids, Liver, Albumins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIEHS NIH HHS, Office of Integrative Activities.
Abstract (Originalsprache)
Perfluorooctanesulfonic acid (PFOS) is a ubiquitous perfluoroalkyl substance (PFAS) linked to liver disease and obesity in humans. Binding studies suggest that albumin is a crucial blood protein influencing PFOS toxicokinetics and hepatotoxicity; however, its role has not been mechanistically tested in vivo. This study used an albumin-deficient mouse model to investigate the relevance of albumin in PFOS tissue distribution and liver disease end points. Adult male C57BL/6J wild-type (Alb+/+) and albumin-deficient (Alb-/-) mice were orally gavaged daily for 7 days with either vehicle or PFOS at 0.5 or 10 mg/kg body weight. The measured PFOS concentrations in plasma were significantly lower in Alb-/- mice compared to those in Alb+/+ mice, while liver concentrations were significantly higher in Alb-/- mice. Binding experiments confirmed these findings, indicating that PFOS toxicokinetics are driven by plasma and tissue binding. Significant changes in liver protein expression did not translate into differences in liver disease end points between genotypes, suggesting the need for chronic exposure studies. Our data imply that disease-related albumin deficiency in humans can influence PFAS toxicokinetics and susceptibility to hepatotoxicity. Our framework using knockout mice can be adapted in future studies to assess the relevance of protein binding and membrane transporters in PFAS distribution and elimination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, 7 Greenhouse Rd, Kingston, Rhode Island 02881, United States.
- Graduate School of Oceanography, University of Rhode Island, Narragansett, Rhode Island 02882, United States.
- Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts 02138, United States.
ORCID-Profile: Jitka Becanova, Rainer Lohmann, Fabian Christoph Fischer, Angela Slitt
Förderung
- NIGMS NIH HHS
- NIEHS NIH HHS
- Office of Integrative Activities
- National Institutes of Health
- National Institute of General Medical Sciences
Zitieren
APA
Kaye, E. M., Becanova, J., Vojta, S., Lohmann, R., Fischer, F. C., & Slitt, A. (2025). Toxicokinetics and Perfluorooctanesulfonic Acid-Induced Liver Protein Expression Are Markedly Altered in Mice Lacking Albumin. Chemical Research in Toxicology, 38(7), 1183-1191. https://doi.org/10.1021/acs.chemrestox.4c00508
Vancouver
Kaye EM, Becanova J, Vojta S, Lohmann R, Fischer FC, Slitt A. Toxicokinetics and Perfluorooctanesulfonic Acid-Induced Liver Protein Expression Are Markedly Altered in Mice Lacking Albumin. Chemical Research in Toxicology. 2025;38(7):1183-1191. doi:10.1021/acs.chemrestox.4c00508
BibTeX
@article{Kaye2025,
author = {Kaye, Emily M and Becanova, Jitka and Vojta, Simon and Lohmann, Rainer and Fischer, Fabian Christoph and Slitt, Angela},
title = {Toxicokinetics and Perfluorooctanesulfonic Acid-Induced Liver Protein Expression Are Markedly Altered in Mice Lacking Albumin},
journal = {Chemical Research in Toxicology},
year = {2025},
volume = {38},
number = {7},
pages = {1183--1191},
doi = {10.1021/acs.chemrestox.4c00508}
}
EUVIMED